Body Barriers to Gene-Based Medicines and Strategies to Improve Lipid Nanoparticles for Treatment

Ionizable lipids enable cytosolic delivery through pH-triggered charge switching, promoting endosomal membrane disruption while remaining neutral in blood to limit nonspecific interactions [13]. Previous studies report that head-group chemistry, apparent pKa, tail saturation and branching, and linker architecture govern packing, phase behavior, and formation of fusogenic or nonlamellar states [14]. Formulations with higher apparent pKa can increase serum binding and clearance, whereas low values reduce endosomal escape, so effective ranges depend on composition [13]. Overly disruptive motifs raise risks of hemolysis and inflammation, so designers must balance escape potency with safety [15]. Rational tuning should couple pKa with lipid ratios and PEG-lipid shedding kinetics for route [16].

Helper phospholipids maintain lamellar structure, reduce leakage, and modulate fusion in lipid-based nanoparticles [11,17]. Previous studies report that high melting species such as DSPC increase rigidity, resist serum-induced destabilization, and improve stability, but can impede membrane fusion and slow endosomal release [11,18]. More unsaturated or shorter chain phospholipids promote fusogenic transitions and cargo release, although they compromise physical stability [17]. The molar ratio of ionizable lipids to cholesterol shapes phase behavior, affecting protein corona formation, biodistribution, and organ tropism [18]. Excess helper content can dilute the ionizable component and depress endosomal escape. Selection should couple stability targets with the intended route and storage constraints [11].

Cholesterol affects the packing, fluidity, and phase behavior of lipid-based nanoparticles, which in turn influences their stability in blood and the probability of endosomal escape [19]. Prior research demonstrates that intermediate fractions promote fusogenic nonlamellar states and reduce leakage, thus improving cytosolic delivery efficiency [20]. Elevated cholesterol levels enhance membrane rigidity, decrease fusion efficiency, and may modify organ tropism by affecting particle deformability and the composition of the protein corona [21]. The interactions of ionizable lipids with helper phospholipids create a balance between lamellar and hexagonal phases, while the chain length and saturation of neighboring lipids affect the organization of cholesterol within the bilayer. Oxidized derivatives and variability in batches pose risks to stability and safety. The formulation seeks to establish equilibrium between circulation durability and endosomal release [22].

PEG-lipids provide steric shielding that reduces opsonization and uptake by the mononuclear phagocyte system, extending circulation while potentially masking ligands and slowing endosomal release [18]. Previous studies report that chain length, surface density, and anchor hydrophobicity control deshielding kinetics and protein corona composition, which govern cellular uptake and escape [23]. High surface coverage or slowly shedding anchors depress delivery, whereas insufficient coverage promotes aggregation and rapid clearance [24]. Immune responses against PEG and accelerated clearance on repeat dosing remain concerns [25]. Effective designs pair modest PEG fractions with cleavable or short anchors coordinated with ionizable lipid content, route, and target tissue. As illustrated in Figure 1, PEG affords transient stealth during circulation while helper phospholipids and cholesterol organize the bilayer and ionizable lipids drive endosomal escape [18]. PEG-lipids are becoming more linked to anti-PEG immune responses, which may speed up blood clearance (ABC) and help keep blood in circulation for longer [26]. One major problem with translating research into practice, especially for long-term medications, is that repeated doses make them much less effective [26]. This is due to treatment-induced or pre-existing anti-PEG antibodies, according to clinical results [27]. PEGylation is a stabilizing method, but it also has a risk that could make it less effective in the long run [28].

Particle size governs dispersion, clearance, and tissue access of lipid-based nanoparticles. Previous studies report that hydrodynamic diameters around 60–120 nm favor prolonged circulation and extravasation, whereas particles below 50 nm undergo rapid renal filtration and those above 200 nm are preferentially sequestered by the mononuclear phagocyte system [29]. Size also modulates lymphatic trafficking after subcutaneous dosing and influences uptake routes and endosomal escape. A single universal optimum is unreliable because endothelial phenotype and enhanced permeability and retention vary by tissue. Effective design controls mean size and polydispersity while anticipating postinjection changes from protein corona formation and aggregation [30]. Reported data should distinguish hydrodynamic and dry diameters and verify stability in serum and under shear so choices align with route and target organ [31].

Lipid-based nanoparticles are often labeled spherical, but composition, mixing kinetics, and payload generate diverse internal architectures including solid cores, inverted micelles, and multilamellar vesicles [20]. Previous studies report that morphology dictates nucleic acid distribution, water content, and phase behavior, which in turn modulate fusion propensity, endosomal escape, and release kinetics [20]. Non-spherical or multilamellar structures can improve stability in blood while slowing cytosolic delivery, whereas loosely packed cores accelerate leakage. Morphology is sensitive to ionizable lipid ratio, cholesterol fraction, buffer and pH during mixing, and can transition under endosomal conditions [32]. Assignments based only on negative stain imaging are unreliable, so characterization should use cryo electron microscopy, tomography, and complementary scattering with explicit reporting of buffers and shear. Design should target forms that balance shelf stability, on-target release, and manufacturability [33].

Surface potential governs serum stability, protein corona formation, aggregation, and cellular interactions of lipid-based nanoparticles, and its interpretation should account for morphology and assay conditions, as shown in Figure 2 [34]. Near-neutral or slightly negative zeta potential limits nonspecific binding and supports longer circulation, whereas strongly positive surfaces increase complement activation, hemolysis risk, and rapid clearance despite enhanced adhesion [35]. Apparent neutrality can suppress uptake and endosomal escape if charge switching is insufficient, and PEG-lipids may mask charge in blood and therefore should be shed at the target [35]. Reported values shift with buffer, ionic strength, pH, temperature, and adsorbed proteins and are sensitive to polydispersity [36]. Rigorous characterization includes electrophoretic mobility with explicit medium composition and verification under physiologic serum and shear [37]. Formulation should coordinate ionizable lipid content, PEG density and anchor length, and buffer selection to balance safe circulation with timely cellular entry.

One of the central paradoxes in lipid nanoparticle (LNP) delivery is that, even when particles are decorated with ligands for active targeting, the adsorbed protein corona can cover these ligands and ultimately determine biological fate [,,]. This masking effect weakens receptor-mediated targeting and remains a major challenge for clinical translation []. Although strategies such as PEGylation, zwitterionic modification, or bioinspired coatings reduce nonspecific protein adsorption, they do not fully eliminate corona formation. In fact, excessive shielding can hinder cellular uptake and limit endosomal escape, creating a delicate balance between circulation stability and target engagement [,]. Interestingly, certain corona constituents, including apolipoprotein E, may promote liver-specific delivery, raising the possibility that corona modulation—rather than complete suppression—could be leveraged to redirect biodistribution []. To move the field forward, systematic studies are required to characterize corona "fingerprints," identify the conditions under which ligand masking is most problematic, and test new approaches such as pre-coating or controlled corona engineering []. Given that corona composition is highly dynamic and varies between patients, resolving this paradox will be critical for achieving consistent and reproducible outcomes with LNP-based nucleic acid therapeutics [,]. ^{30 42 44 45 42 45 43 46 44 47}

PEGylation has long been employed to prolong the circulation of lipid nanoparticles, yet the emergence of anti-PEG antibodies and the accelerated blood clearance (ABC) phenomenon continue to represent major barriers to clinical translation. Upon repeated dosing, both IgM and IgG responses can be elicited against PEG, which promotes opsonization, rapid removal from the bloodstream, and a significant decline in therapeutic performance. These issues are especially problematic for chronic indications where multiple administrations are required over time []. To mitigate such challenges, attention has shifted toward alternative stealth materials including poly(2-oxazoline), poly(glycerol), polysarcosine, and zwitterionic polymers, each of which has shown the potential to maintain circulation benefits with lower immunogenicity [,]. It is also becoming increasingly clear that the "stealth effect" is not an absolute property but depends strongly on PEG density, chain length, and conformational arrangement. Recent analyses highlight that striking the right balance between extended circulation and efficient cellular uptake will be critical for achieving successful translation of LNP-based therapeutics []. These circulation and clearance dynamics, along with organ-level biodistribution patterns, are illustrated in. ^{51 28 52 51} Figure 4

A recent study demonstrated that the biophysical density and heterogeneity of the extracellular matrix (ECM), in conjunction with the physicochemical stability of nanoparticle formulations, influence penetration and treatment effects []. A recent study of extracellular vehicles (EVs) has shown that storage conditions and their surroundings affect the recovery, integrity, and functional activity of these vesicles []. Lipid-based nanoparticles (LNPs) can become less stable, and their interactions can be deformed upon exposure to heterogeneous extracellular matrix (ECM) networks in vivo []. Under adverse conditions, protein adsorption, vesicle fusion, or aggregation can enhance complex transport pathways inside collagen- and glycosaminoglycan-rich matrices []. Therefore, the integration strategy should consider both ECM remodeling (e.g., enzyme or physical modulation) and formulation stabilization (e.g., optimized buffer system, cryoprotectant, or dynamic coating) to preserve functional delivery []. This dual perspective that connects extracellular transport barriers with physicochemical conservation gives a complete framework for making nanomedical devices that can be used in medicine []. ^{65 18 18 30 64 18}

Ionizable lipids govern whether lipid nanoparticles achieve cytosolic delivery without provoking systemic toxicity by switching charge and packing as pH changes along the endocytic route [99]. At physiological pH, they remain largely neutral and adopt a cylindrical geometry that supports lamellar organization and circulation stability, whereas endosomal acidification increases protonation and drives an inverted cone geometry that favors nonlamellar transitions and membrane mixing as depicted in Figure 9 [100]. Performance depends not only on pKa near the mildly acidic range but also on headgroup sterics, linker chemistry, and hydrophobic tail architecture that together determine curvature stress, miscibility with helper lipids, and the balance between stability and fusogenicity [100]. Formulations that strongly promote hexagonal HII phases can improve escape while risking premature destabilization, protein adsorption, and hemolysis, and highly compacted cores shield RNA from nucleases while potentially delaying uncoating at ribosomes [101]. Designs that incorporate biodegradable ionizable lipids can reduce tissue retention, although metabolite profiles and durability of gene expression require careful evaluation [101]. Emerging architectures such as multication switching or double ionization motifs are promising for stronger endosomal engagement but may narrow the dosing window and raise safety concerns. Effective optimization, therefore, aligns pKa and molecular shape with trafficking kinetics, preserves cargo proximity to lipids during maturation, and enables timely decomplexation after release, accepting that gains in escape often trade off against colloidal stability and tolerability [102].

Helper phospholipids and cholesterol shape membrane packing, rigidity, and curvature in lipid nanoparticles and therefore influence circulation stability, protein corona formation, organ distribution, and endosomal release of nucleic acids [18]. Prior studies report that saturated phosphatidylcholines such as DSPC maintain particle morphology and limit premature leakage under physiological conditions, although the higher order they impose can suppress the negative curvature needed for membrane fusion during endosomal escape [17]. In contrast, helper lipids with unsaturation or phosphatidylethanolamine headgroups promote nonlamellar transitions that facilitate fusion and pore formation, while increasing the risk of aggregation and unintended membrane damage, which can lower tolerability [18]. Cholesterol fills packing defects and tunes membrane order and elasticity, but its fraction presents a narrow window because excessive amounts can dampen tumorgenicity and slow release whereas insufficient amounts compromise integrity and increase leakage [24]. Chemically modified cholesterol derivatives offer finer control of elasticity and phase propensity and can improve deformation during tissue passage, although shifts in pharmacokinetics and innate immune activation require monitoring [103]. An effective formulation co-optimizes helper lipid headgroups and acyl chains with cholesterol type and content to match trafficking and escape kinetics, accepting that improvements in endosomal release often trade off against colloidal stability and safety and therefore benefit from iterative testing in models that reflect the intended route and target tissue [2].

PEG-lipids confer steric stabilization that limits opsonization and prolongs circulation, but their density, chain length, and anchor chemistry jointly determine how well lipid nanoparticles reach and engage target cells [18]. High surface coverage suppresses nonspecific protein binding and reticuloendothelial uptake while also creating a hydration barrier that reduces ligand access, membrane contact, and endosomal escape [23]. Low coverage improves interactions with cells but increases aggregation, complement activation, and rapid clearance [37]. The hydrophobic tail of the PEG-lipid governs desorption kinetics from the particle surface, where shorter or biodegradable anchors shed more readily after extravasation to expose charge or ligands, and longer anchors resist shedding and sustain stealth at the cost of weaker uptake [23]. Environmentally responsive designs that cleave PEG through hydrolysis, redox change, or mild acidity can reconcile these opposing needs when the trigger is synchronized with tissue access, although premature loss during circulation or incomplete removal in the target site undermines the benefit [37]. Repeated dosing introduces additional constraints because anti-PEG responses and accelerated clearance have been observed, which argues for careful control of PEG density and for evaluation of mixed stealth strategies such as combining PEG with zwitterionic or polyglycerol motifs [15]. Continued treatment not only speeds up clearance because of anti-PEG immunity, but it also makes long-term safety and effectiveness worse in chronic cases [26]. This event has caused many clinical projects to fail, which means that there should be different covert strategies [104]. Zwitterionic polymers, poly(2-oxazoline), polyglycerols, and degradable PEG analogs are some of the most recent attempts to create a stealth effect while making the immune system less likely to react [28]. Researchers are also looking into PEG designs that are temporary or can be cleaved, as well as mixed stealth coatings, to find a balance between stability in the first circulation and less ABC when redoing [105]. For LNP therapies to be effective in real-world applications, these strategies and vigilant monitoring of anti-PEG antibody titters are essential [106]. Effective optimization balances circulation stability with timely unmasking by tuning PEG length, surface fraction, and anchor composition to match trafficking and exposure windows while monitoring safety, immunogenicity, and reproducibility in models that reflect the intended route and organ target [37].

One of the biggest problems with moving PEGylated LNPs from the lab to the clinic is the development of anti-PEG immunity, which is shown by the accelerated blood clearance (ABC) phenomenon [26]. Many people already have anti-PEG antibodies, and taking more of them may make these immune reactions worse [27]. This poses a significant threat to clinical translation, particularly for chronic diseases requiring frequent or prolonged dosing, as subsequent doses of PEGylated nanoparticles often demonstrate modified biodistribution, reduced therapeutic efficacy, and diminished circulation half-lives [107]. This paradox highlights PEG's dual function: it prolongs systemic circulation and provides steric stabilization, but it also induces immunogenicity that compromises sustained delivery [28,108]. The fact that ABC has already interrupted or ended a number of promising therapeutic programs, according to clinical observations, highlights how serious the problem is [109]. There have been several suggestions for how to make these problems less severe. Other stealth coatings that are less likely to cause an immune response, such as poly(2-oxazoline), polyglycerols, and zwitterionic polymers, have also been shown to extend circulation [110]. Also, degradable or cleavable PEG analogs that are shed after tissue extravasation can make it harder for antibodies to recognize the initial protection [109]. To find a balance between stable circulation and lower ABC levels after redosing, researchers are looking into mixed stealth coatings that use PEG and other polymers [111]. Additionally, optimized dosing regimens, decoy particles, and meticulous monitoring of anti-PEG antibody titters have been proposed as adjunctive strategies to mitigate the clinical effects of ABC. In general, PEGylation should be seen as both a way to make circulation more stable and a possible problem that limits its long-term use [110]. Future LNP development will benefit from systematic evaluation of anti-PEG immune responses, integration of alternative polymers, and adaptive dosing strategies to ensure sustainable clinical translation [112].

Hepatocyte-directed delivery builds on the liver's propensity to clear nanoparticles while guiding carriers to productive uptake by parenchymal cells rather than sequestration by Kupffer cells or sinusoidal endothelium [48]. N-acetylgalactosamine ligands that engage the asialoglycoprotein receptor on hepatocytes enable efficient clathrin-mediated internalization and permit subcutaneous administration by maintaining targeting after systemic exposure, although performance depends strongly on ligand density, spatial orientation, and linker chemistry that governs receptor access and avidity [113]. Overcrowded presentation can create a steric canopy that limits membrane contact and slows endosomal escape, whereas sparse or weakly attached ligands are displaced by protein corona components and redirect particles to off-target sinks [113]. Endogenous pathways can be leveraged by tuning surface charge and lipid composition to promote apolipoprotein adsorption and low-density lipoprotein receptor engagement, which enhances hepatocyte uptake but increases sensitivity to biological variability in corona formation [114]. Design choices must balance affinity, pharmacokinetics, and intracellular routing because high-affinity binding can trap particles at the cell surface and favor recycling, and aggressive charge exposure improves uptake while elevating complement activation. Practical formulations, therefore, pair GalNAc or complementary motifs with controlled ligand spacing, cleavable linkers that unmask the surface after extravasation, and ionizable lipid cores that support endosomal escape, while accounting for disease-dependent changes in receptor expression and sinusoidal architecture that alter targeting efficiency across patient populations [113].

Active targeting of lipid nanoparticles to immune and tumor compartments seeks to convert heterogeneous accumulation into productive uptake by defined cell subsets while avoiding sequestration by the mononuclear phagocyte system [114]. Ligands such as antibodies, single-chain fragments, peptides, aptamers, or small molecules can be displayed to engage markers on dendritic cells, T cells, tumor-associated macrophages, or malignant cells, enabling receptor-mediated endocytosis and localized gene modulation as illustrated in Figure 10 [114]. Performance depends on how ligands are presented because density, spacing, and orientation determine receptor access and avidity, and excessive crowding or persistent PEG layers can hinder binding and dampen endosomal escape, whereas sparse coverage invites displacement by the protein corona and redirection to off-target sinks [18]. The tumor microenvironment introduces additional barriers including variable receptor expression, high interstitial pressure, and stromal shielding, which collectively lower the fraction of particles that reach intended cells and can bias trafficking toward lysosomal degradation [115]. Designs that use cleavable PEG, multivalent or bispecific constructs, pH or protease-responsive linkers, and locally administered or intratumoral dosing can improve engagement, although these same features may raise complement activation, accelerate clearance on repeat dosing, or increase immunogenicity if Fc domains or highly cationic surfaces are exposed [116]. Balancing affinity, pharmacokinetics, and intracellular routing while accounting for disease-dependent changes in myeloid composition and vascular integrity is therefore essential for reliable immune-cell or tumor-specific delivery by lipid nanoparticles [114].

Conventional lipid nanoparticles preferentially localize to the liver owing to sinusoidal fenestration, apolipoprotein adsorption, and efficient uptake by hepatocytes and resident phagocytes, so redirecting distribution requires control over surface chemistry without sacrificing stability [79]. Selective organ targeting modulates biodistribution by adding a small fraction of permanently charged or zwitterionic lipids during formulation, which shifts effective surface charge, alters protein corona composition, and biases receptor engagement, as summarized in Figure 11 [117]. Cationic additives can favor delivery to lungs or spleen, whereas specific anionic or zwitterionic components can increase access to lymphoid or marrow tissues, providing a modular route that does not depend on ligands [118,119]. This flexibility introduces trade-offs because small changes in identity or molar percent can move particles outside a narrow window for colloidal integrity, trigger complement activation, or reduce potency through excessive PEG shielding, and corona variability across sera can undermine predictability between models and patients [4]. Practical implementation, therefore, hinges on tight manufacturing control of additive ratios, orthogonal analytics that track corona profiles and charge in physiological media and pairing of SORT chemistry with endosomal escape capacity, so tissue retuning does not come at the cost of intracellular release [118]. Combining SORT with local dosing or conditional PEG shedding can further improve target engagement if toxicity, repeat-dose clearance, and disease-dependent vascular changes are evaluated in relevant models [98]. Although progress with SORT systems has been encouraging, their consistency across species and disease models is still uncertain [18]. Even subtle shifts in formulation, or changes in the protein corona that form in different biological fluids, can redirect organ tropism and make outcomes difficult to predict [120]. The addition of permanently charged lipids, while useful for returning biodistribution, also reduces the margin for colloidal stability and alters corona composition in ways that may affect uptake pathways and immune recognition [2]. To manage these risks, more careful analytical tools and testing in physiologically relevant settings are needed. For clinical translation, the most practical opportunities are likely in diseases where regional or catheter-based dosing can be applied, alongside SORT chemistries that integrate feasible endosomal-escape strategies. Reaching first-in-human studies will depend on strict control of formulation ratios and demonstration of reproducibility across multiple centers [18].

Ionizable lipids enable lipid nanoparticles to remain neutral at physiological pH for low systemic reactivity and to gain positive charge during endosomal acidification, where protonation strengthens interactions with anionic membranes and promotes fusion or transient pore formation that releases nucleic acids [121]. Delivery performance reflects not only pKa near the mildly acidic range of roughly 6 to 6.5 but also headgroup sterics, linker chemistry, and tail geometry that bias curvature and nonlamellar phase formation, with well-known lipids such as DLin-MC3-DMA illustrating this balance around pKa 6.4 [2]. These same features introduce trade-offs because increased fusogenicity can reduce colloidal stability, raise hemolysis risk, and trigger off-target membrane perturbation, while a narrow activation window and heterogeneous extracellular acidosis can lead to premature lipid protonation before cellular uptake [122]. The tumor milieu complicates matters further, as shown in Figure 12, where abnormal vasculature drives hypoxia and acidity that may favor activation but also limits perfusion, whereas vascular normalization improves oxygenation and raises pH, narrowing the window for pH-triggered release [123]. Effective designs, therefore, couple pKa-matched ionizable lipids with helper lipids that tune curvature without excessive leakage, preserve cargo proximity during trafficking, and allow timely decomplexation in the cytosol, with dosing schedules adapted to tissue physiology so gains in escape do not come at the expense of safety or exposure [2,122].

Cell-penetrating and fusogenic motifs are used to boost endosomal escape of lipid nanoparticle cargo by either promoting membrane merger or creating local osmotic and curvature stress that opens transient pores [124]. Representative peptides such as INF7, S19, and TAT fusions can undergo pH-triggered conformational changes in maturing endosomes that favor insertion and disruption, and cationic polymers including polyhistidine, protamine, and PAMAM enhance buffering and membrane destabilization while condensing nucleic acids [125,126]. These additions increase cytosolic delivery but introduce trade-offs that matter in practice because peptide density, orientation, and anchoring chemistry can impair colloidal stability, increase serum protein binding, and shift biodistribution, and strong membrane activity risks hemolysis, mitochondrial injury, and inflammation [126]. Quantitative essays that read out true cytosolic access such as SLEEQ report low escape fractions in common cell lines on the order of only a few percent, which argues for measured claims and for pairing these agents with ionizable lipid cores rather than relying on them as stand-alone solutions [127]. Strategies that mask charges with cleavable PEG, restrict activity to acidic or protease-rich niches, and use biodegradable polymer backbones can maintain circulation stability while enabling on-target activation, although incomplete triggering or premature unmasking reduces the benefit [125,128]. Effective designs therefore tune peptide or polymer loading and placement to complement, not overwhelm, the ionizable lipid mechanism, with escape gains weighed against safety, manufacturability, and reproducibility across relevant models [128].

Lipid nanoparticles can be configured to dampen unwanted immunity or induce antigen-specific tolerance by co-delivering small molecules, protein or peptide antigens, and programmed mRNA while matching the formulation to the tissue reached and the cell types engaged [129]. Co-loading rapamycin with cognate antigen has been shown to bias dendritic cells toward regulatory programs and expand regulatory T cells, and nucleoside-modified mRNA reduces innate sensing to further curb reactogenicity [130]. Figure 13 illustrates a lymph node–addressable design in which Pam2Cys-incorporated mRNA-LNPs concentrate expression in draining nodes after intradermal dosing, supporting localized immune programming, while Table 8 summarizes how route selection shapes biodistribution and immune activation with intramuscular delivery driving systemic responses, intravenous delivery biasing hepatic expression with limited stimulation, and subcutaneous delivery focusing activity in draining lymph nodes [114]. These gains require balance because excessive immunosuppression risks infection, persistent PEG layers can hinder receptor access in nodes, and strongly membrane-active components that boost endosomal escape can reduce tolerability [131]. Practical regimens therefore tune cargo ratios, release kinetics, PEG shedding, and dosing route and verify antigen-specific T-cell and antibody outcomes rather than relying on surrogate readouts alone [114,130].

Administration route and dose determine where lipid nanoparticles distribute, which antigen-presenting cells are engaged, and how strongly innate and adaptive programs are activated, making delivery planning part of the therapeutic mechanism rather than a neutral choice [132]. Intravenous delivery concentrates exposure in the liver through sinusoidal filtration and apolipoprotein interactions and suits hepatocyte targets while higher doses raise the risk of systemic reactogenicity [133]. Intramuscular injections produce strong local expressions with drainage to regional lymph nodes and measurable spillovers to liver and spleen, which supports broad immunity but increases off-target expression as dose escalates [134]. Subcutaneous or intradermal dosing focuses activity in draining lymph nodes and can be tuned toward tolerance with low repeated doses, although onset is slower and varies with injection depth and volume [134], whereas inhalation positions payloads in the airways where epithelial cells and phagocytes dominate uptake under constraints imposed by mucociliary clearance and irritancy [135]. Schedule further shapes outcomes because spaced low doses often improve T cell persistence and memory compared with a single large dose that heightens cytokines and complement and can saturate endosomal pathways, yielding diminishing returns [136]. Repeated administration introduces constraints including anti-PEG responses and accelerated clearance, which call for careful control of PEG density and shedding kinetics, interval selection, and premedication when appropriate [137]. Effective regimens align route, volume, and device with tissue access, pair dose with endosomal escape capacity to avoid trafficking bottlenecks and confirm antigen-specific function and safety in models that reflect disease-dependent physiology [132,134].

Microfluidic synthesis allows precise control over the assembly of lipid nanoparticles for nucleic acid delivery, with performance tightly linked to how streams are combined and diluted [38]. The flow rate ratio, defined as the volumetric rate of the aqueous phase relative to the organic solvent, governs antisolvent dilution and nucleation; higher values usually drive rapid desolvation that produces smaller particles near the 30–40 nm range with low polydispersity, although excessive dilution can weaken core formation, lower encapsulation efficiency, and broaden size when neutralization is mistimed [138]. The total flow rate sets mixing time and Reynolds number; faster operation often narrows distributions but raises shear and pressure, increases heat generation, and can aggravate channel fouling or stress-sensitive RNA [139]. Intensified micromixer geometries such as staggered herringbone and vortex-inducing designs improve reproducibility and process stability while introducing device variability and cleaning validation burdens during scale-up [138,140]. Composition and environment intersect with hydrodynamics because of lipid concentration, ethanol fraction, buffer pH and ionic strength, and temperature shift assembly pathways and endow different packing states; cooler or low-solvent conditions can yield larger particles through slower lipid rearrangement, whereas moderate warmth increases membrane mobility at the risk of cargo degradation [141]. Studies that map delivery against flow conditions show that an FRR–TFR pair that maximizes in vivo potency does not always coincide with the smallest size or highest encapsulation, underscoring that mixing must be tuned with the intended route, endosomal escape capacity, and stability constraints [142]. Practical implementation, therefore, combines tight control of FRR and TFR with at-line analytics, robust device qualification, and numbering-up strategies that preserve residence time distributions, accepting trade-offs between colloidal stability, encapsulation yield, and manufacturability under GMP [38,139].

Long-term stabilization of lipid nanoparticles for nucleic acid delivery depends on controlling chemical degradation of lipids and RNA and preventing physical instabilities that appear as growth in hydrodynamic size, loss of encapsulation, or altered surface charge during storage [143]. Lyophilization with disaccharide protectants such as sucrose or trehalose preserves structure by vitrifying the matrix and replacing water at the membrane interface, which maintains particle integrity through freezing and drying and allows reconstitution with minimal change in size distribution when excipient to lipid ratios and residual moisture are optimized [144]. Benefits are not automatic because buffer species can crystallize during freezing and drive pH excursions that accelerate RNA hydrolysis and ionizable lipid breakdown, and rapid primary drying or overly warm secondary drying can collapse the cake and impair redispersion [145]. Storage at refrigerated temperature after successful freeze-drying supports retention of mRNA translation capacity and colloidal properties, although oxygen ingress and trace metals promote oxidation, which argues for oxygen-barrier packaging, judicious emissions, and avoidance of reactive headspace [146]. Formulation variables intersect with process settings since ethanol carryover, lipid composition, and nucleic acid length influence glass transition and protectant needs, and reconstitution medium, ionic strength, and temperature determine whether aggregates form on thawing [147]. Practical development, therefore, selects buffers with stable freezing behavior, sets conservative primary and secondary drying endpoints based on product temperature and glass transition, targets low residual moisture that still permits rapid redispersion, and confirms stability under accelerated and in-use conditions including repeated needle aspiration and simulated transport [144,147]. These controls expand distribution beyond ultracold chains and reduce costs while acknowledging trade-offs because higher sugar loads increase tonicity and prolonged drying can damage cargo, so process parameters must be tuned alongside chemistry to deliver durable and readily reconstituted lipid nanoparticle therapeutics [144,148]. Turning a laboratory concept into a product that can be manufactured under GMP conditions is never simple. Once production is scaled up, critical quality attributes (CQAs) such as particle size, RNA integrity, encapsulation efficiency, and surface charge can drift, sometimes enough to affect safety or performance [149]. Keeping these factors under control requires more than optimized mixing or improved stabilization. It also depends on real-time analytics, clearly defined release standards, and early integration with regulatory frameworks [150]. Without these safeguards, even the most promising designs may remain impressive in the lab but fail to advance toward clinical or commercial use [149,150].